Wellington Chen, M.D. of Advanced Rejuvenation Introduces Stem Cell Therapy For OsteoArthritis & COPD in Sarasota …
Sarasota, Florida (PRWEB) June 18, 2013 After almost 20 years of performing regenerative treatments in the field of non surgical orthopedics, Wellington Chen, M.D., will begin conducting clinical trials for many degenerative diseases using adipose-derived stem cell therapy in Sarasota, Florida. The independent review board of the International cell medicine society is responsible for overseeing these trials. Advanced Rejuvenation will treat patients suffering from chronic obstructive pulmonary disease (COPD) and osteoarthritis following the IRB-approved protocols.
Some biotechnology companies have grumbled about the legal challenge to their right to patent genes, arguing that taking away that right could impede innovation. But now that the US Supreme Court has ruled companies cant patent genes, the decision has been largely met with a collective shrug from the biopharmaceutical industry. Thats because the high court ruling continues to allow drug companies to patent the technologies that enable them to turn genetic research into medicines
PORT ST. LUCIE, Fla.–(BUSINESS WIRE)– Scientists at the Vaccine & Gene Therapy Institute of Florida (VGTI Florida) have been awarded three new federal research grants that will further support the Institutes mission of Translating Research Into Health
‘Mountain Astrologer’ Magazine Publishes Investigative Feature on History of Monsanto and Genetic Engineering of Food
KINGSTON, N.Y., June 18, 2013 /PRNewswire/ –How did Monsanto become so powerful? How is such a relatively small company so influential? These are among the questions asked in “In Through the Out Door: The Cosmic Signature of Monsanto and GMOs,” an investigative feature written by Eric Francis Coppolino, editor of Planet Waves
Now that the Supreme Court has ruled that merely isolating a DNA sequence does not make it eligible to patent, the question arises, What will happen to the crucially important data accumulated by an overly broad monopoly? The answer to this question has implications for people who may have an inherited risk for breast and ovarian cancer and to the scientists who hope to use that data for life-saving decisions about cancer surgery.
Public release date: 18-Jun-2013 [ | E-mail | Share ] Contact: Aaron Lohr firstname.lastname@example.org 240-482-1380 The Endocrine Society Similar genetic variations occur in both overweight newborns and obese adults, a large study finds. The results will be presented Tuesday at The Endocrine Society’s 95th Annual Meeting in San Francisco.
Findings may lead to the ability to give newborns a “genetic score” on obesity risk factors.
Vatican conference: “New frontiers of genetics and the risk of eugenics” The progress of science must not lose sight of the human person.
Fixing Muscle Imbalances and Muscle Attachment (Genetics) I cover four points in this video.
The Zacks Analyst Blog Highlights: Myriad Genetics, Anika Therapeutics, Biogen Idec , Alexion Pharmaceuticals and …
For Immediate Release Chicago, IL June 18, 2013 Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets.
The issue of when or where canines were domesticated has geneticists in a tug of war. Image: Les Hirondelles Photography/Flickr/Getty Images How does a Venus flytrap know when to snap shut? Can it actually feel an insects tiny, spindly legs
Scientists have discovered and amplified an evolved adeno-associated virus (AAV) to target and deliver gene therapy to retinal cells in mice. This discovery could lead to less invasive and more precise gene therapies for retinal degeneration diseases such as retinoschisis and Lebers congenital amaurosis, as well as disease in other organs that normally couldnt be treated with gene therapy because of the lack of tissue specific drug delivery systems. This study, which was published in Science Translational Medicine and reported by TheScientist.com, is still in animal trials but has already been praised because of its potential to improve the outcome of gene therapy as well as to expand the use of gene therapy to other diseases.
Public release date: 15-Jun-2013 [ | E-mail | Share ] Contact: Aaron Lohr email@example.com 240-482-1380 The Endocrine Society A new genetic test accurately and consistently diagnoses benign growths, or nodules, on the thyroid gland, according to a study from Chile. The results will be presented Saturday at The Endocrine Society’s 95th Annual Meeting in San Francisco. “We have developed a ‘gene signature’ that effectively identifies benign thyroid nodules,” said Hernan Gonzalez, MD, PhD, associate professor at the Pontifical Catholic University of Chile in Santiago.
Public release date: 17-Jun-2013 [ | E-mail | Share ] Contact: Keith Herrell firstname.lastname@example.org 513-558-4559 University of Cincinnati Academic Health Center CINCINNATIThe University of Cincinnati’s (UC) environmental health department has received an $8.7 million federal grant to continue operating its Center for Environmental Genetics (CEG). Led by Shuk-mei Ho, PhD, director, the CEG supports state-of-the-art core facilities and technologies needed to conduct innovative research that focuses on how environmental agents interact with genetic and epigenetic factors to influence disease risk and outcome. This funding renewal, from the National Institutes of Health’s National Institute of Environmental Health Sciences (NIEHS), will be dispersed in annual increments of about $1.74 million through March 31, 2018.
Last month, Angelina Jolie stunned the world with a New York Times op/ed titled, My Medical Choice. Angelina confessed she had undergone a preventative double mastectomy and breast reconstruction as a result of learning that she carries the BRCA1 gene mutation and therefore had an 87% risk of breast cancer.
Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor …
NEW YORK, June 17, 2013 /PRNewswire/ — Reportlinker.com announces that a new market research report is available in its catalogue: Personalized Medicine Diagnostics (Flow Cytometry, Sepsis Immunos, Routine Coagulation, Psychiatric Disorders, Tumor Markers, Molecular Blood Typing and Other Testing) http://www.reportlinker.com/p01360928/Personalized-Medicine-Diagnostics-Flow-Cytometry-Sepsis-Immunos-Routine-Coagulation-Psychiatric-Disorders-Tumor-Markers-Molecular-Blood-Typing-and-Other-Testing.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic Personalized Medicine Diagnostics – Market Overview Personalized Medicine is often defined as “the right treatment for the right person at the right time.” Personalized medicine is becoming the place to be in clinical diagnostics as well and slowly becoming the reality of future in the diagnostics industry By Technology Segment – Personalized Medicine diagnostics market is expected to grow with a double digit CAGR for the period of 2013 to 2018. It is expected that personalized medicine diagnostics market by technology is going to double by 2018 from its current market size in 2012.
Log in to manage your products and services from The New York Times and the International Herald Tribune. Don’t have an account yet?
Human Genetics – Blood Type Video I had some trouble with iMovie but the articles referenced are as follows: cassiopaea.org https://cassiopaea.org/forum/index.ph… http://en.wikipedia.org/wi..
Let's Play: The Sims 3 Perfect Genetics Challenge – (Part 3) – She's one Pregnaunt Girl! fill in later. By: TheBigSimTheory
Atossa Genetics has entered into a contractual agreement with HealthSmart, a Preferred Provider Organization network serving clients in all 50 states. The agreement with HealthSmart affords preferred providers and their patients with greater access to Atossa’s ForeCYTE Breast Health Test by ensuring timely reimbursement for the laboratory costs associated with the test
SEATTLE, WA–(Marketwired – Jun 17, 2013) – Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, has entered into a contractual agreement with HealthSmart, a Preferred Provider Organization (PPO) network serving clients in all 50 states. The agreement with HealthSmart affords preferred providers and their patients with greater access to Atossa’sForeCYTE Breast Health Test by ensuring timely reimbursement for the laboratory costs associated with the test
Los Angeles, California (PRWEB) June 16, 2013 According to a May 29, 2013 NBC News article, titled Gene Therapies for Regenerative Surgery Are Getting Closer, Says Review in Plastic and Reconstructive Surgery, researchers have made significant progress in the development of gene therapy techniques that can grow skin, bone and tissue for reconstructive surgery. Researchers from Padua University Hospital in Italy who conducted the review claim the potential benefits of using gene therapy in reconstructive surgery are numerous. (Go to goo.gl/kYjFa) According to the article, gene therapy may be instrumental in solving a problem that most plastic and reconstructive surgeons face, which is the lack of sufficient tissue to correct deformities that patients have in certain areas of their body